U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H38FN2O2
Molecular Weight 465.6226
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of AZD-9164

SMILES

C[C@@](N1CCCCC1)(C(=O)O[C@H]2C[N+]4(CCC3=CC=C(F)C=C3)CCC2CC4)C5=CC=CC=C5

InChI

InChIKey=FNYFFCOCVNTJCD-NNMXADRKSA-N
InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1

HIDE SMILES / InChI

Description

AZD9164 was invented by AstraZeneca as a muscarinic M(3) receptor antagonist for evaluation of the potential as a treatment for chronic obstructive pulmonary disease. However, in 2010 studies were discontinued.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
2017-02
Overcoming non-specific adsorption issues for AZD9164 in human urine samples: consideration of bioanalytical and metabolite identification procedures.
2012-04-15
The discovery of AZD9164, a novel muscarinic M3 antagonist.
2011-12-15

Sample Use Guides

In Vivo Use Guide
Solution for inhalation through nebulization, single dose. AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
Route of Administration: Other
Name Type Language
AZD9164
Preferred Name English
AZD-9164
Common Name English
AZD 9164 [WHO-DD]
Common Name English
J3.232.015E
Code English
1-AZONIABICYCLO(2.2.2)OCTANE, 1-(2-(4-FLUOROPHENYL)ETHYL)-3-((2S)-1-OXO-2-PHENYL-2-(1-PIPERIDINYL)PROPOXY)-, (3R)-
Systematic Name English
1-(4-FLUOROPHENETHYL)-3.BETA.-((S)-2-PHENYL-2-(1-PIPERIDINYL)PROPIONYLOXY)QUINUCLIDINIUM
Systematic Name English
Code System Code Type Description
CAS
1034978-04-5
Created by admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
PRIMARY
PUBCHEM
44517831
Created by admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
PRIMARY
FDA UNII
977LWC4O5D
Created by admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
PRIMARY
DRUG BANK
DB12115
Created by admin on Mon Mar 31 23:07:35 GMT 2025 , Edited by admin on Mon Mar 31 23:07:35 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of AZD-9164
SALT/SOLVATE (PARENT)
Structure of AZD-9164 BROMIDE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966